Movement Alert｜BIOCYTOGEN-B Rises 6.15% in Regular Trading, H1 Net Profit Surges Over 400% Amid Nanobody Licensing Catalyst

Market Focus09-14

On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.

The rally was underpinned by strong H1 earnings and a recent licensing collaboration. The company reported H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.29% to RMB 241 million, marking the fifth consecutive profitable quarter. Preclinical products and services revenue reached RMB 723.5 million, up 57.9%, with innovative animal model sales growing 62.4% at an 82.3% gross margin. Antibody discovery revenue rose 33.8% to RMB 217.9 million, maintaining a 92.8% gross margin.

Additionally, the company recently signed a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule generated by its proprietary RenNano platform, targeting neurological drug development. The H1 earnings briefing disclosed over 105 new cooperation agreements signed during the period, with further acceleration expected in the second half.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111724563?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 14:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111724563","market":"us","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 6.15% in Regular Trading, H1 Net Profit Surges Over 400% Amid Nanobody Licensing Catalyst","media":"Market Focus","content":"<p><p>On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.</p><p>The rally was underpinned by strong H1 earnings and a recent licensing collaboration. The company reported H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.29% to RMB 241 million, marking the fifth consecutive profitable quarter. Preclinical products and services revenue reached RMB 723.5 million, up 57.9%, with innovative animal model sales growing 62.4% at an 82.3% gross margin. Antibody discovery revenue rose 33.8% to RMB 217.9 million, maintaining a 92.8% gross margin.</p><p>Additionally, the company recently signed a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule generated by its proprietary RenNano platform, targeting neurological drug development. The H1 earnings briefing disclosed over 105 new cooperation agreements signed during the period, with further acceleration expected in the second half.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 6.15% in Regular Trading, H1 Net Profit Surges Over 400% Amid Nanobody Licensing Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 6.15% in Regular Trading, H1 Net Profit Surges Over 400% Amid Nanobody Licensing Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 14:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.</p><p>The rally was underpinned by strong H1 earnings and a recent licensing collaboration. The company reported H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.29% to RMB 241 million, marking the fifth consecutive profitable quarter. Preclinical products and services revenue reached RMB 723.5 million, up 57.9%, with innovative animal model sales growing 62.4% at an 82.3% gross margin. Antibody discovery revenue rose 33.8% to RMB 217.9 million, maintaining a 92.8% gross margin.</p><p>Additionally, the company recently signed a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule generated by its proprietary RenNano platform, targeting neurological drug development. The H1 earnings briefing disclosed over 105 new cooperation agreements signed during the period, with further acceleration expected in the second half.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1111724563","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111724563","pubTimestamp":1789366557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.The rally was underpinned by strong H1...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势警报|BIOCYTOGEN-B 常规交易上涨 6.15%，纳米抗体授权催化剂上半年净利润飙升超 400%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On September 14, BIOCYTOGEN-B rose 6.15% in regular trading to HKD 59.55, with turnover of HKD 78.744 million, rebounding after consecutive sessions of pullback.The rally was underpinned by strong H1 earnings and a recent licensing collaboration. The company reported H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.29% to RMB 241 million, marking the fifth consecutive profitable quarter. Preclinical products and services revenue reached RMB 723.5 million, up 57.9%, with innovative animal model sales growing 62.4% at an 82.3% gross margin. Antibody discovery revenue rose 33.8% to RMB 217.9 million, maintaining a 92.8% gross margin.Additionally, the company recently signed a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule generated by its proprietary RenNano platform, targeting neurological drug development. The H1 earnings briefing disclosed over 105 new cooperation agreements signed during the period, with further acceleration expected in the second half.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111724563","isCrawlerRequest":true}